Sign in
Taking people in United StatesPhase 2

Roflumilast foam for children and teens with non-segmental vitiligo

Tests roflumilast foam on the skin of young people with non-segmental vitiligo.

Key facts

Who runs it
Derm Texas, PLLC
Where
Dallas, United StatesSee the site
Trial code
Registry title
An Open-label Single Center, Proof of Concept Study Evaluating the Efficacy of Roflumilast Foam 0.3% in Pediatric Patients With Non-Segmental Vitiligo (NSV)
Status
Recruiting
Phase
Phase 2
People taking part
20 people, planned
Started
1 Aug 2025
Planned end
15 Jun 2026
Type of study
Interventional
Treatments tested
  • Roflumilast topical 0.3% foam
Record updated
8 August 2025

Who can take part

AI summary

From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.

The trial is looking for children and teens with non-segmental vitiligo, including on the face. They will use Roflumilast foam 0.3% on the skin.

Age
2 years to less than 18 years
Sex
All sexes
Disease stage
Non-segmental vitiligo diagnosed for at least 3 months. Less than 10% of the body skin is affected, with at least 0.5% on the face. Some face patches still have coloured hair.
Earlier treatment
Cannot join after Roflumilast cream or foam for vitiligo in the past 3 months, or oral roflumilast within 4 weeks. Biologic or experimental therapy must stop 12 weeks (or 5 half-lives) before, light therapy and immune-changing treatments 4 weeks before, and skin treatments 1 week before.

Main reasons for not taking part

  • Other types of vitiligo or other skin conditions that cause light patches
  • Severe kidney problems or moderate to severe liver problems (Child-Pugh B or C)
  • Allergy to an ingredient of Roflumilast foam
  • Cannot stop CYP3A4 inhibitor medicines taken by mouth or other routes
  • Pregnant, planning pregnancy or breastfeeding

The registry criteria, word for word

Show all 18 criteriaShow less

Who can take part

  • Male or female subjects aged 2 years but less than 18 years
  • Pediatric and adolescent subjects: Informed consent of parent(s) or legal guardian, and, if age appropriate, assent by the subjects, as required by local laws
  • Diagnosis of non-segmental vitiligo based on clinical history and dermatology examination for at least 3 months
  • Diagnosis of non-segmental vitiligo with the following:; BSA affected < 10% AND; At least 0.5% BSA affected on the face. AND; Pigmented hair within some of the areas of vitiligo on the face
  • In good health as judged by the Investigator, based on the medical history, and dermatology examination
  • Subjects and parent(s)/legal guardian (s) are considered reliable and capable of adhering to the Protocol and visit schedule, according to the judgment of the Investigator

Who cannot take part

  • Subjects with known or suspected:; Severe renal insufficiency; Moderate to severe hepatic disorders (Child-Pugh B or C); Subjects who cannot discontinue prohibited medications and treatments prior to the Baseline visit and during the study, including (any biologic or experimental therapy within 12 weeks (or 5 half-lives), phototherapy within 4 weeks, immunomodulating treatments within 4 weeks, or topical treatments within 1 week
  • Subjects who are unwilling to refrain from using a tanning bed or other artificial light emitting devices (LEDs) for 4 weeks prior to Baseline/Day 1 and during the study
  • Subjects who cannot discontinue systemic CYP3A4 inhibitors or dual inhibitors that inhibit both CYP3A4 and CYP1A2 simultaneously (e.g. Erythromycin, ketoconazole, fluvoxamine, enoxacin, cimetidine)
  • Subjects who have received oral roflumilast (Daxas®, Daliresp®) within 4 weeks prior to Baseline/Day 1
  • Previous treatment with Roflumilast cream or foam for vitiligo in the past 3 months
  • Subjects with any serious medical condition or physical examination abnormality that would prevent study participation or place the subject at significant risk, as judged by the Investigator
  • Subjects with diagnosis of other forms of vitiligo (e.g. Segmental), other differential diagnosis of vitiligo or other skin depigmentation disorders (e.g. Piedbaldism, pityriasis alba, leprosy, post-inflammatory hypopigmentation, progressive macule hypomelanosis, nevus anemicus, chemical leukoderma and tinea versicolor) that would interfere with the evaluations of the effect of the study medication, as determined by the Investigator
  • Subjects with known genetic dermatological conditions that overlap with non-segmental vitiligo
  • Known allergies to excipients in Roflumilast foam (petrolatum, isopopyl palmitate, methylparaben, propylparaben, diethylene glycol monomethyl ether, hexylene glycol, cetylseteary alcohol, dicetyl phosphase and ceteth-10 phosphate)
  • Parent (s)/legal guardians (s) who are unable to communicate, read, or understand the local language (s). Subjects who are unable to communicate, read or understand the local language, or who display another condition, which in the Investigator's opinion, makes them unsuitable for clinical study participation
  • Females who are pregnant, wishing to become pregnant during the study, or are breast feeding
  • Subjects who are family members of the clinical study site, clinical study staff, or sponsor, or family members of enrolled subjects living in the same house

Check if you might fit

Answer for yourself. This is not a decision: only the study team can say whether you can take part.

  • Are you between 2 and 18 years old?

Where in United States

  • Derm TexasDallas, United StatesContact: Amanda Study CoordinatorTaking people

About the trial

What the trial wants to find out

An open-label single center, proof of concept study evaluating the efficacy of Roflumilast foam 0.3% in pediatric subjects with Non-Segmental Vitiligo (NSV)

The group in the trial

  • Open-label single center, proof of concept study evaluating the efficacy of Roflumilast foam 0.3%Treatment being tested

    Treatment: Roflumilast topical 0.3% foam

Questions to ask the study team

  1. How often do I need to come in, and for how long each time?
  2. Are travel costs paid?
  3. Can I keep my own doctor?
  4. What happens if I want to stop?

Contact the study team: see the registry record → Contacts and Locations

Print a page for my doctor

Data and sources

Registry record
Listed on ClinicalTrials.gov.How to verify a trial in the registry
Official title
An Open-label Single Center, Proof of Concept Study Evaluating the Efficacy of Roflumilast Foam 0.3% in Pediatric Patients With Non-Segmental Vitiligo (NSV)
Plain-language title
Roflumilast foam for children and teens with non-segmental vitiligoGenerated from the registry record. The registry title is the official one.
AI summary
From the trial's eligibility criteria. Read by machine on 14 November 2026.
Fit questions
Built from NCT07105254, who can take part
Record updated
8 August 2025